Decera Clinical Education Oncology Podcast

In this episode, Suzanne Lentzsch, MD, Ph. D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of:  Considerations with administration, including access challenges Sequencing Therapies Future dev...

In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including: Overall approach to treatment Use of JAK inhibitors for treating myelofibrosis Treating patients with low platelets Defining JAK inhibitor failure Unmet needs in treatment and emerging therapeutic options, including momeloti...

In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of:    Data supporting the use of adjuvant PARP inhibition in early breast cancer and impact on B...

In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including: Expression patterns and function of the claudin family of proteins in normal gastric tissues Biologic rationale for utility of claudin 18.2...

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia.  The topics covered include: When to use cytoreduction therapies and which therapies to use in low-risk patients Type 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reports Experts’ thought...

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia. Topics di...

In this podcast episode, Steven M. Horwitz, MD; Pamela B. Allen, MD, MSc; and Kerry Savage, MD, MSc, answer questions from an audience of healthcare professionals on topics related to the management of T-cell lymphomas, including: Use of brentuximab vedotin in ≤1% CD-30‒expressing lymphomas Strategies with JAK inhibition and epigenetic agents Allogeneic transplantation in cutaneous T-cell lymphoma...

In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including:   Practical use of the Molecular International Prognostic Scoring System   Mutational targets and other treatments in ongoing clinical trials Prophylaxis with ve...

In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including: Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC  Clinical implications of PD-L1 status on therapeutic planning for...

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include: Patient presentation and goals of frontline therapy Considerations for second-line therapy in the setting of treatment intolerance Experts’ thoughts on the potential of early intervention to alter diseas...

In this episode, David Kaplan, MD, MSc, and Tamar Taddei, MD, discuss which patients should be screened for hepatocellular carcinoma, current surveillance recommendations, barriers to implementation, emerging biomarkers in development, and unmet needs in hepatocellular carcinoma surveillance.  Presenters: David E. Kaplan, MD, MSc Associate Professor Perelman School of Medicine Chief, Hepatology Se...

In this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience.  Presenter: Zoe Lanham Patient Link to full program: https://bit.ly/3Fukjzk Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information a...

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including: • Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer   • Geneva HRD test: validation of samples from PAOLA-1 dataset using Genev...

In this episode, activist and breast cancer survivor Yee Won Chong shares his experience as a transmasculine person navigating the healthcare system with Norma Steiner, MD, a gynecologic oncologist, who in turn offers her perspective on caring for patients across the gender spectrum. Topics include: 4 aspects of transgender care: emotional, social, medical, legal Getting language right and how to...

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include: Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today Relevance of overall response...

In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of: GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil...

In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including: Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancer Phase III CALLA trial: durvalumab comb...

In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include: How to sequence currently available therapies after relapse Challenges with using BCMA-targeted agents in clinica...

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including: Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placebo Phase III ENGOT-ov25/PAOLA-1: final OS results from the trial of main...

In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on: • Identifying patients who may benefit the most from adjuvant osimertinib   • Testing for EGFR mutations in early-stage NSCLC • Critical importance of getting molecular test...

In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:  BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutini...

In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include: Factors to consider before selecting frontline immunotherapy Role of TKIs in the frontline Impact of Child-Pugh status on the efficacy of immunotherapy/VEGF in...

In this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer. The discussion includes:  Optimizing systemic therapy for patients with HER2-positive early breast cancer based on disease characteristics and risk Sequencing available therapies for patients with HER2-positive metastatic di...

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:  GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL FLAIR: randomized, a...

In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of:  The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance i...